News & Updates

No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
15 Sep 2024
Diabetes, insulin use up risk of death, cardiac events in AF patients
Diabetes, insulin use up risk of death, cardiac events in AF patients
14 Sep 2024
Vitamin D deficiency tied to higher T2D risk
Vitamin D deficiency tied to higher T2D risk
09 Sep 2024

Increased serum concentration of 25(OH)D appears to contribute to a reduced risk of type 2 diabetes (T2D) across the glycaemic spectrum below the threshold for diabetes, reports a study. Improving the lipid profile may be partly responsible for the favourable association.

Vitamin D deficiency tied to higher T2D risk
09 Sep 2024
SGLT-2 inhibitors may prevent dementia in adults with T2D
SGLT-2 inhibitors may prevent dementia in adults with T2D
07 Sep 2024 byStephen Padilla

Initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors results in a 35-percent reduced risk of dementia compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in individuals with type 2 diabetes (T2D) aged 40–69 years, according to a study. In addition, greater benefits are seen with longer treatment duration.

SGLT-2 inhibitors may prevent dementia in adults with T2D
07 Sep 2024